Our promise to you:
Guaranteed product quality, expert customer support.
Viral vectors are efficient tools for modification of eukaryotic cells, and they are now used to introduce genes into mature T cells to generate immunity to cancer through the delivery of chimeric antigen receptors (CARs) or cloned T-cell receptors. Lentiviral vectors, derived from the human immunodeficiency virus, have been extensively investigated and optimized over the past two decades. CAR-T cell therapies engineered using lentiviral vectors have demonstrated noteworthy clinical success in patients with B-cell malignancies, leading to regulatory approval of the first genetically engineered cellular therapy using lentiviral vectors.
However, lentiviral infection of primary T cells is always a challenging task. Although lentiviral vectors are capable of transducing T-cells in the quiescent growth phase, increased transduction efficiency can be achieved only if the T-cells are activated through T-cell receptor activation and/or by cytokines. This limitation undoubtedly increases the difficulty of CAR‐T cell construction.
CAR Lentiviral Services at Creative Biogene
Lentivirus packaging team in Creative Biogene has extensive experience in lentivirus related work. We have carried out systematic optimization in the aspects of increasing the ability of lentivirus to carry exogenous genes, improving the affinity of lentivirus to cells from different tissue sources, and enhancing the production and titer of lentivirus. The lentivirus constructed by our platform is proven via FACS to be able to infect T cells efficiently. Creative Biogene provides one-stop service to offer ultra high titer lentivirus production service for CAR-T cell therapies.
Figure 1 Generation process for CAR-T cells.
(Anti-Cancer Drugs 2016)